Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net (loss) income	$ (291,754)	$ (287,100)	$ 132,244
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	3,699	3,454	2,888
Stock-based compensation expense	50,737	51,364	38,160
Write-off of prepaid manufacturing services related to the termination of CHS-2020		3,210
Inventory write-offs, net	26,000	5,133	2,171
Non-cash interest expense from amortization of debt discount & issuance costs	6,431	4,257	3,481
Upfront and option payments to Junshi Biosciences	35,000	136,000
Other upfront and milestone based license fee payments			7,500
Loss on debt extinguishment	6,222
Other non-cash adjustments, net	1,798	3,890	2,352
Changes in operating assets and liabilities:
Trade receivables, net	13,052	34,062	(15,218)
Inventory	(47,348)	(6,253)	(38,359)
Prepaid manufacturing	(4,214)	3,828	(10,851)
Other prepaid, current and non-current assets	(13,424)	(5,351)	(2,020)
Accounts payable	(4,548)	874	(9,820)
Accrued rebates, fees and reserves	(24,566)	(2,502)	30,409
Accrued compensation	596	(230)	6,212
Accrued and other current and non-current liabilities	1,195	17,932	4,996
Net cash (used in) provided by operating activities	(241,124)	(37,432)	154,145
Investing activities
Purchases of property and equipment	(2,039)	(1,289)	(7,231)
Proceeds from disposal of property and equipment			175
Purchases of investments in marketable securities	(127,382)	(182,485)	(273,845)
Proceeds from maturities of investments in marketable securities		99,692	274,000
Proceeds from sale of investments in marketable securities		81,672
Upfront and option payments to Junshi Biosciences	(35,000)	(136,000)
Other upfront and milestone based license fee payments	(2,429)		(7,500)
Net cash used in investing activities	(166,850)	(138,410)	(14,401)
Financing activities
Proceeds from issuance of 2026 Convertible Notes, net of issuance costs			222,156
Proceeds from 2027 Term Loans, net of debt discount & issuance costs	240,679
Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs		40,903
Proceeds from issuance of common stock under ATM Offering, net of issuance costs	6,358
Proceeds from issuance of common stock upon exercise of stock options	691	10,399	17,428
Proceeds from purchase under the employee stock purchase plan	2,320	3,002	3,801
Purchase of capped call options related to 2026 Convertible Notes			(18,170)
Taxes paid related to net share settlement of RSUs	(3,744)	(1,753)	(880)
Repayment of 2022 Convertible Notes and premiums	(109,000)
Repayment of 2025 Term Loan, premiums and exit fees	(81,750)
Other financing activities	(1,228)	(672)	(389)
Net cash provided by financing activities	54,326	51,879	223,946
Net (decrease) increase in cash, cash equivalents and restricted cash	(353,648)	(123,963)	363,690
Cash, cash equivalents and restricted cash at beginning of period	417,635	541,598	177,908
Cash, cash equivalents and restricted cash at end of period	63,987	417,635	541,598
Supplemental disclosure of cash flow information
Cash paid for interest	34,878	18,684	16,959
Cash paid for income taxes	40	1,221	3,953
Right-of-use assets obtained in exchange for lease obligations related to operating leases		434	1,388
Right-of-use assets obtained in exchange for lease obligations related to finance leases	2,694	477	1,817
Supplemental disclosures of non-cash investing and financing activities
Purchase of property and equipment in accounts payable and accrued liabilities	$ 32	$ 119	109
Non-cash employee bonuses settled in common stock			$ 1,498